AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22658401 — intervention group
Group type: EXPERIMENTAL
Intervention: Almorexant (200 mg p.o.)
Number of subjects: 20
Study 22658401 — intervention group
Group type: EXPERIMENTAL
Intervention: Almorexant (200 mg p.o.) with ethanol (0.6 g/L i.v. ethanol clamp for 5 h)
Number of subjects: 20
Study 22658401 — intervention group
Group type: COMPARATOR
Intervention: Ethanol (0.6 g/L i.v. ethanol clamp for 5 h)
Number of subjects: 20
Study 21768546 — intervention group
Group type: EXPERIMENTAL
Intervention: sirolimus‐ and probucol‐eluting stents
Number of subjects: 3002
Study 21768546 — intervention group
Group type: COMPARATOR
Intervention: zotarolimus‐eluting stents
Number of subjects: 3002
Study 19143675 — intervention group
Group type: EXPERIMENTAL
Intervention: BufferGel (BG; ReProtect Inc., Baltimore, Maryland)
Number of subjects: 81
Study 19143675 — intervention group
Group type: EXPERIMENTAL
Intervention: ACIDFORM (Instead Inc., La Jolla, CA, USA)
Number of subjects: 81
Study 19143675 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo gel (K‐Y Jelly; Personal Products Inc., Raritan, NJ, USA)
Number of subjects: 81
Study 16397514 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil monotherapy
Number of subjects: 179
Study 16397514 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil/HCTZ double therapy
Number of subjects: 179
Study 16397514 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil/HCTZ/Amlodipine besylate triple therapy
Number of subjects: 179
Study 15106393 — intervention group
Group type: EXPERIMENTAL
Intervention: Nine-week group cognitive-behavioral therapy (CBT) intervention
Number of subjects: 38
Study 15106393 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 38
Study 11358906 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon therapy (leucocytic interferon alfa, escalating schedule for 12 months)
Number of subjects: 72
Study 11358906 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 72
Study 11358906 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon therapy
Number of subjects: 72
Study 9446402 — intervention group
Group type: EXPERIMENTAL
Intervention: Myoelectrical activity measurement using two serosal electrodes in ischaemic bowel
Number of subjects: 26
Study 9446402 — intervention group
Group type: EXPERIMENTAL
Intervention: Resected ischaemic bowel submitted to histological examination
Number of subjects: 26
Study 8181261 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide (NCT) 25 mg kg‐1 day‐1
Number of subjects: 90
Study 8181261 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide (NCT) 25 mg kg‐1 day‐1 + Cyclosporin (CyA) 5 mg kg‐1 day‐1
Number of subjects: 90
Study 8181261 — intervention group
Group type: COMPARATOR
Intervention: Insulin only (Control)
Number of subjects: 90
Study 3063587 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium aspartate (Mg 5‐Longoral) at a daily dose of 15 mmol
Number of subjects: 985
Study 3063587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 985
Study 30476320 — intervention group
Group type: EXPERIMENTAL
Intervention: SNAP intervention training on implementing a policy promoting active recreation (AR)
Number of subjects: 76
Study 30476320 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard control)
Number of subjects: 76
Study 30476320 — intervention group
Group type: EXPERIMENTAL
Intervention: SNAP intervention
Number of subjects: 76
Study 28132971 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable lumbosacral support
Number of subjects: 121
Study 28132971 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 121
Study 26210806 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-Eluting Stents (EES)
Number of subjects: 1800
Study 26210806 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-Eluting Stents (PES)
Number of subjects: 1800
Study 24021709 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Carbohydrate (HC) diet (60-65% carbohydrates, 20-25% fats)
Number of subjects: 30
Study 24021709 — intervention group
Group type: COMPARATOR
Intervention: Moderately Restricted Carbohydrate (MRC) diet (43-47% carbohydrates, 36-40% fats)
Number of subjects: 30
Study 24021709 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 30
Study 21745006 — intervention group
Group type: EXPERIMENTAL
Intervention: Coherent sentences presented in speech envelope/spectrum noise at varying SNR
Number of subjects: 0
Study 21745006 — intervention group
Group type: COMPARATOR
Intervention: Anomalous sentences presented in speech envelope/spectrum noise at varying SNR
Number of subjects: 0
Study 19373653 — intervention group
Group type: EXPERIMENTAL
Intervention: Oblimersen/dexamethasone (N = 110)
Number of subjects: 224
Study 19373653 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone alone (N = 114)
Number of subjects: 224
Study 16771960 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem 500 mg t.i.d. started at admission (group A)
Number of subjects: 215
Study 16771960 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B) - antibiotics started after demonstration of necrosis
Number of subjects: 215
Study 15273638 — intervention group
Group type: EXPERIMENTAL
Intervention: One-visit endodontic treatment (including a 10‐min intraappointment dressing with 5% iodine‐potassium‐iodide)
Number of subjects: 96
Study 15273638 — intervention group
Group type: COMPARATOR
Intervention: Two-visit endodontic treatment (including an interappointment dressing with calcium‐hydroxide paste)
Number of subjects: 96
Study 11744449 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention for patients and physicians (mailed newsletters, face-to-face visits, printed manuals, and pamphlets)
Number of subjects: 2402
Study 11744449 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 2402
Study 11744449 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention for physicians
Number of subjects: 2402
Study 11744449 — intervention group
Group type: COMPARATOR
Intervention: Control group (physicians without educational intervention)
Number of subjects: 2402
Study 9427904 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-feeding
Number of subjects: 38
Study 9427904 — intervention group
Group type: COMPARATOR
Intervention: Formula-feeding
Number of subjects: 38
Study 7912102 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg twice daily for 7 days)
Number of subjects: 20
Study 7912102 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (5 mg twice daily for 7 days)
Number of subjects: 20
Study 7912102 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg twice daily for 7 days)
Number of subjects: 20
Study 7912102 — intervention group
Group type: COMPARATOR
Intervention: Comparison of metoprolol with pindolol and propranolol
Number of subjects: 20
Study 3579530 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated behavioral therapy
Number of subjects: 29
Study 3579530 — intervention group
Group type: COMPARATOR
Intervention: Traditional physical therapy (Bobath therapeutic exercises)
Number of subjects: 29
Study 31322732 — intervention group
Group type: EXPERIMENTAL
Intervention: Response-adaptive allocation procedure
Number of subjects: 0
Study 30587148 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined physical exercise and psychosocial intervention (24 individual physical exercise sessions and 6 psychosocial training sessions for children, 2 for parents)
Number of subjects: 68
Study 30587148 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 68
Study 27013152 — intervention group
Group type: COMPARATOR
Intervention: Conservative strategy
Number of subjects: 258
Study 27013152 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive strategy
Number of subjects: 258
Study 24727052 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially available CCA urine-cassette assay
Number of subjects: 500
Study 24727052 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental CCA urine-cassette assay
Number of subjects: 500
Study 24727052 — intervention group
Group type: COMPARATOR
Intervention: Kato-Katz faecal smear method (gold-standard)
Number of subjects: 500
Study 24325697 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser debulking (LD) + drug-eluting balloon (DEB) angioplasty
Number of subjects: 48
Study 24325697 — intervention group
Group type: COMPARATOR
Intervention: Drug-eluting balloon (DEB) angioplasty alone
Number of subjects: 48
Study 20885017 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg/day, i.v.) for 10 days starting on day 1 after ischemic stroke
Number of subjects: 60
Study 20885017 — intervention group
Group type: COMPARATOR
Intervention: No vitamin C therapy (Control group)
Number of subjects: 60
Study 18065424 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 30
Study 18065424 — intervention group
Group type: COMPARATOR
Intervention: Diet
Number of subjects: 30
Study 21314440 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral combination of desmin (300 mg/day) and troxerutin (300 mg/day) with Centella asiatica (30 mg/day) and Melilotus (160 mg/day) for 14 months
Number of subjects: 40
Study 21314440 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 40
Study 15921225 — intervention group
Group type: EXPERIMENTAL
Intervention: dilator spring‐loaded nasal strip
Number of subjects: 150
Study 15921225 — intervention group
Group type: COMPARATOR
Intervention: placebo device
Number of subjects: 150
Study 12351469 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity progressive resistance training plus moderate weight loss (RT & WL group)
Number of subjects: 36
Study 12351469 — intervention group
Group type: COMPARATOR
Intervention: Moderate weight loss plus a control program (WL group)
Number of subjects: 36
Study 9872188 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous conjugated estrogens (1.25 mg)
Number of subjects: 20
Study 9872188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7619669 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 200 mg
Number of subjects: 182
Study 7619669 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 300 mg
Number of subjects: 182
Study 7619669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 2694332 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine 150 mg b.i.d.
Number of subjects: 60
Study 2694332 — intervention group
Group type: EXPERIMENTAL
Intervention: cimetidine 400 mg b.i.d.
Number of subjects: 60
Study 868455 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclofenil
Number of subjects: 60
Study 868455 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol valerate
Number of subjects: 60
Study 868455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 11600740 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid Arthritis Quality of Life (RAQoL) questionnaire applied to patients with increasing difficulty in performing activities of daily living
Number of subjects: 510
Study 11600740 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid Arthritis Quality of Life (RAQoL) questionnaire applied to patients with stable disease
Number of subjects: 510
Study 30694962 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week static stretching (SS) program for the hamstrings (SS intervention group; n = 15)
Number of subjects: 30
Study 30694962 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group; n = 15)
Number of subjects: 30
Study 31443789 — intervention group
Group type: EXPERIMENTAL
Intervention: Voretigene neparvovec-rzyl (VN) gene therapy, 1.5×10^11 vector genomes (vg) per eye, subretinal injection.
Number of subjects: 40
Study 30261008 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (2 × 850 mg) for 7 days
Number of subjects: 18
Study 26786203 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein intake (>30g) at each meal
Number of subjects: 67
Study 26786203 — intervention group
Group type: COMPARATOR
Intervention: Traditional weight loss regimen (Control)
Number of subjects: 67
Study 24725989 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 40
Study 24725989 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no laser power)
Number of subjects: 40
Study 22584629 — intervention group
Group type: EXPERIMENTAL
Intervention: DP + stent
Number of subjects: 58
Study 22584629 — intervention group
Group type: COMPARATOR
Intervention: DP
Number of subjects: 58
Study 20452031 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10mg daily for 12 weeks
Number of subjects: 42
Study 20452031 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram treatment
Number of subjects: 42
Study 20452031 — intervention group
Group type: COMPARATOR
Intervention: Depressed patients who remitted
Number of subjects: 42
Study 20452031 — intervention group
Group type: COMPARATOR
Intervention: Non-depressed controls
Number of subjects: 42
Study 17666283 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 15681939 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg/kg rFVIIa
Number of subjects: 204
Study 15681939 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 microg/kg rFVIIa
Number of subjects: 204
Study 15681939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 14513291 — intervention group
Group type: EXPERIMENTAL
Intervention: [123I]IPT administration
Number of subjects: 15
Study 14513291 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal adults)
Number of subjects: 15
Study 10543589 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic lavage
Number of subjects: 30
Study 10543589 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 30
Study 8901178 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (n = 26)
Number of subjects: 52
Study 8901178 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (n = 26)
Number of subjects: 52
Study 8901178 — intervention group
Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 52
Study 8901178 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 52
Study 1671241 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient ischaemic attacks with a history suggestive of lacunar ischaemia
Number of subjects: 606
Study 1671241 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacunar symptoms
Number of subjects: 606
Study 1671241 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical infarcts
Number of subjects: 606
Study 1671241 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacunar TIAs
Number of subjects: 606
Study 6896646 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of allopurinol (1H‐pyrazolo‐(3,4‐d) pyrimidin‐4‐ol) administered orally for 7 days
Number of subjects: 10
Study 29149793 — intervention group
Group type: EXPERIMENTAL
Intervention: DEMIAN nursing intervention, 2 training days
Number of subjects: 180
Study 29149793 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 180
Study 30532258 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantum Trajectories Method (QTM) using MPI technology
Number of subjects: 0
Study 27417288 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.7 mg/day rhGH for 40 weeks
Number of subjects: 46
Study 27417288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 24508285 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse facilitated cognitive behavioural self‐management programme
Number of subjects: 260
Study 22196131 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 Gy EBRT
Number of subjects: 247
Study 22196131 — intervention group
Group type: EXPERIMENTAL
Intervention: 44 Gy EBRT
Number of subjects: 247
Study 22196131 — intervention group
Group type: COMPARATOR
Intervention: Both 20 Gy and 44 Gy EBRT
Number of subjects: 247
Study 19762016 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted learning module
Number of subjects: 242
Study 19762016 — intervention group
Group type: COMPARATOR
Intervention: Conventional face-to-face teaching methods
Number of subjects: 242
Study 17407159 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated plasma TIMP‐1 levels
Number of subjects: 251
Study 17407159 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher TIMP‐1 plasma levels (analyzed as a continuous variable)
Number of subjects: 251
Study 17407159 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated plasma TIMP‐1 level
Number of subjects: 251
Study 16223204 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEP lecithin gel (1.3%) applied 5 g t.i.d. for 10 days
Number of subjects: 158
Study 16223204 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied 5 g t.i.d. for 10 days
Number of subjects: 158
Study 12511851 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvisomant (Somavert(R))
Number of subjects: 0
Study 10447627 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (600 cGy single dose between 2nd and 4th postoperative day)
Number of subjects: 154
Study 10447627 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (2 x 50 mg per day from 1st to 42nd postoperative day)
Number of subjects: 154
Study 10447627 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 154
Study 8647478 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic group
Number of subjects: 2
Study 8647478 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2
Study 2233916 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (40 mg) every 6 hours for 7 days
Number of subjects: 23
Study 2233916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 535845 — intervention group
Group type: EXPERIMENTAL
Intervention: d-triiodothyronine during a 1000-calorie diet
Number of subjects: 0
Study 535845 — intervention group
Group type: COMPARATOR
Intervention: Dietary treatment alone
Number of subjects: 0
Study 535845 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (diet + d-triiodothyronine)
Number of subjects: 0
Study 31770148 — intervention group
Group type: EXPERIMENTAL
Intervention: High PEEP (15 cm H2O)
Number of subjects: 48
Study 31770148 — intervention group
Group type: COMPARATOR
Intervention: Conventional PEEP (5 cm H2O)
Number of subjects: 48
Study 30670737 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 10629
Study 30670737 — intervention group
Group type: EXPERIMENTAL
Intervention: Body fat percentage
Number of subjects: 10629
Study 30670737 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal metabolic rate
Number of subjects: 10629
Study 30670737 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure
Number of subjects: 10629
Study 30670737 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting glucose
Number of subjects: 10629
Study 30670737 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density lipoprotein cholesterol
Number of subjects: 10629
Study 30670737 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein cholesterol
Number of subjects: 10629
Study 30670737 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure
Number of subjects: 10629
Study 30670737 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cholesterol
Number of subjects: 10629
Study 30670737 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglycerides
Number of subjects: 10629
Study 30670737 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference
Number of subjects: 10629
Study 27093128 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentalization-based treatment (MBT) adherence and competence
Number of subjects: 15
Study 27093128 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist interventions directed toward exploring mental states
Number of subjects: 15
Study 26354540 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified DASH diet rich in plant protein (18% protein, two-thirds plant sources)
Number of subjects: 62
Study 26354540 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified DASH diet rich in animal protein (18.4% protein, two-thirds animal sources)
Number of subjects: 62
Study 26354540 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-protein diet (27% protein, two-thirds animal sources)
Number of subjects: 62
Study 26354540 — intervention group
Group type: COMPARATOR
Intervention: Healthy American diet (HAD)
Number of subjects: 62
Study 25001663 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutraceutical combination (red yeast rice, Silybum marianum, octasonol)
Number of subjects: 134
Study 23251327 — intervention group
Group type: EXPERIMENTAL
Intervention: 6EH (ethambutol 800 mg and isoniazid 300 mg daily for six months)
Number of subjects: 712
Study 23251327 — intervention group
Group type: COMPARATOR
Intervention: 36H (isoniazid 300 mg daily for 36 months)
Number of subjects: 712
Study 23251327 — intervention group
Group type: EXPERIMENTAL
Intervention: 6EH
Number of subjects: 712
Study 23251327 — intervention group
Group type: EXPERIMENTAL
Intervention: 6EH among TST-positive subjects
Number of subjects: 712
Study 23251327 — intervention group
Group type: EXPERIMENTAL
Intervention: 6EH and 36H
Number of subjects: 712
Study 23251327 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmed TB cases
Number of subjects: 712
Study 18805589 — intervention group
Group type: EXPERIMENTAL
Intervention: High blood pressure
Number of subjects: 41
Study 18805589 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 41
Study 17854338 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard DISP with mandatory vehicle sale, but without electronic monitoring (Group 2)
Number of subjects: 477
Study 17854338 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard DISP with electronic monitoring, but without mandatory vehicle sale (Group 3)
Number of subjects: 477
Study 17854338 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard DISP without electronic monitoring or mandated vehicle sale (Group 4)
Number of subjects: 477
Study 17854338 — intervention group
Group type: COMPARATOR
Intervention: Standard DISP with electronic monitoring and vehicle sales requirements (Group 1)
Number of subjects: 477